Aprea Therapeutics Stock News

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy

Zacks Investment Research lowered shares of Aprea Therapeutics (NASDAQ:APRE) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, []

Zacks Investment Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a hold rating to a buy rating in a research note issued to investors on Friday morning, Zacks.com reports. The brokerage currently has $3.75 target price on the stock. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and []

BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of Aprea Therapeutics, Inc. (Nasdaq: APRE) lead product candidate, eprenetapopt .

Zacks Investment Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a hold rating to a buy rating in a report released on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $4.25 target price on the stock. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel []

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

The FDA removed the full clinical hold on Aprea Therapeutics Inc''s (NASDAQ: APRE ) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. The agency issued a

Aprea Therapeutics Inc. (NASDAQ:APRE) price on Thursday, December 09, rose 1.00% above its previous days close as an upside momentum from buyers pushed the stocks value to $4.16. A look at the stocks price movement, the level at last check in todays session was $4.12, moving within a range at $3.8499 and $4.315. The beta Thinking Of Buying Aprea Therapeutics Inc. (NASDAQ: APRE) Stock? Heres What You Need To Know Read More »

The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid

The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) increased by over 14% during intraday trading today. This is why it happened.

Aprea Therapeutics (NASDAQ:APRE) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Wednesday, Zacks.com reports. The firm presently has a $4.25 price target on the stock. Zacks Investment Researchs price target would indicate a potential upside of 3.41% from the companys previous close. According to []

Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Gregory Alan Korbel sold 27,500 shares of Aprea Therapeutics stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $3.96, for a total value of $108,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through this []

The Boeing Company (BA) with the stream of -5.41% also noticed, India Aprea Therapeutics, Inc. (APRE) encountered a rapid change of -3.49% in the last hour of Fridays trading session. The post Hot Stock to Observe: The Boeing Company (NYSE:BA), Aprea Therapeutics, Inc. (NASDAQ:APRE) appeared first on Stocks Equity .

Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) have been assigned a consensus recommendation of Hold from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year price objective among analysts []